Table 1. Demographic and Clinical Characteristics of Mother—Infant Pair Study Participants.
| n = 879 | % Total | |||
| Result Lab SOC | Negative | 788 | 89.6% | |
| Positive | 57 | 6.5% | ||
| Rejected sample/New Collection | 22 | 2.5% | ||
| Missing result | 12 | 1.4% | ||
| Result POC | Negative | 825 | 93.9% | |
| Positive | 47 | 5.3% | ||
| Invalid | 4 | 0.5% | ||
| Missing result | 3 | 0.3% | ||
| Groups | ||||
| % HIV+a | n = 879 | % Total | ||
| Health clinics | CS 1 DE JUNHO | 4.4% | 250 | 28.4% |
| CS 1 DE MAIO | 4.4% | 252 | 28.7% | |
| CS POLANA CANICO | 9.3% | 377 | 42.9% | |
| Age (in months) | 1–2 months | 2.6% | 540 | 61.6% |
| 2–3 months | 9.1% | 143 | 16.3% | |
| 3–6 months | 10.1% | 129 | 14.7% | |
| 6–9 months | 13.2% | 38 | 4.3% | |
| > 9 months | 44.4% | 27 | 3.1% | |
| Sex | Female | 7.0% | 471 | 53.6% |
| Male | 5.9% | 408 | 46.4% | |
| Mother's prophylaxis | None | 28.6% | 14 | 1.6% |
| Option Ab | 16.2% | 138 | 15.7% | |
| Option B+c (ART) | 5.2% | 610 | 69.4% | |
| Missing Data | 5.1% | 117 | 13.3% | |
| Infant's prophylaxis | None | 46.2% | 13 | 1.5% |
| NVPd | 6.1% | 674 | 76.7% | |
| NVP + AZT | 50.0% | 2 | 0.2% | |
| AZTe | 5.3% | 19 | 2.2% | |
| Missing Data | 4.7% | 171 | 19.5% | |
| Infant's breastfeeding | No | 9.1% | 99 | 11.3% |
| Yes | 7.1% | 548 | 62.3% | |
| Missing Data | 3.9% | 232 | 26.4% | |
a: HIV status based on the SOC test result.
b: WHO recommended set which includes: Antepartum-AZT starting as early as 14 weeks gestation, Intrapartum-at onset of labour, sdNVP and first dose of AZT/3TC, Postpartum- daily AZT/3TC through 7 days postpartum
c: Option that include ART as treatment regimen
d: Single dose of Nevirapine
e: Zidovudine